We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Laboratory Corp of America Holdings (LH) Com Stk USD0.1

Sell:$206.08 Buy:$206.51 Change: $0.47 (0.23%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.47 (0.23%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.47 (0.23%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Laboratory Corporation of America Holdings provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.

Contact details

United States
+1 (336) 2291127

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$17.31 billion
Shares in issue:
84.13 million
Health Care Services
New York Stock Exchange
United States
US dollar

Key personnel

  • Adam Schechter
    Chairman of the Board, President, Chief Executive Officer
  • Glenn Eisenberg
    Chief Financial Officer, Executive Vice President
  • Thomas Pike
    President, Chief Executive Officer - Clinical Development Business Unit
  • Mark Schroeder
    Executive Vice President, President Diagnostics and Chief Operations Officer
  • Judith Seltz
    Chief Human Resource Officer, Executive Vice President
  • Lance Berberian
    Executive Vice President, Chief Information and Technology Officer
  • Amy Summy
    Executive Vice President, Chief Marketing Officer
  • Brian Caveney
    Executive Vice President, President Early Development and Chief Medical and Scientific Officer
  • Sandra van Der Vaart
    Executive Vice President, Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
  • Peter Wilkinson
    Senior Vice President, Chief Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.